Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development

[1]  J. Hubbell,et al.  Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. , 2017, Virology.

[2]  N. Sardesai,et al.  A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever , 2017, Human vaccines & immunotherapeutics.

[3]  L. Ehlkes,et al.  Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016 , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  Donald S. Grant,et al.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.

[5]  Kenneth O. Logan,et al.  Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Kate E. Jones,et al.  Understanding the cryptic nature of Lassa fever in West Africa , 2017, Pathogens and Global Health.

[7]  K. Chandran,et al.  Structural basis for antibody-mediated neutralization of Lassa virus , 2017, Science.

[8]  J. Koehler,et al.  Laboratory Diagnosis of Lassa Fever , 2017, Journal of Clinical Microbiology.

[9]  S. K. Fehling,et al.  Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany , 2016, Genome Announcements.

[10]  Donald S. Grant,et al.  Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. , 2016, Antiviral research.

[11]  I. Lukashevich,et al.  Vaccine platforms to control Lassa fever , 2016, Expert review of vaccines.

[12]  Pardis C Sabeti,et al.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits , 2016, Nature Communications.

[13]  S. Günther,et al.  New Hosts of The Lassa Virus , 2016, Scientific Reports.

[14]  H. Feldmann,et al.  Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali , 2016, Emerging infectious diseases.

[15]  P. Maes,et al.  Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea , 2016, PLoS medicine.

[16]  S. Günther,et al.  Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever , 2015, The Journal of infectious diseases.

[17]  Epidemic focus: Lassa Fever. , 2016, Releve epidemiologique hebdomadaire.

[18]  H. Feldmann,et al.  The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset , 2015, Scientific Reports.

[19]  N. Forrester,et al.  Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage , 2015, Front. Microbiol..

[20]  Elizabeth M. Ryan,et al.  Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus , 2015, Cell.

[21]  D. Krüger,et al.  Lassa Virus in Multimammate Rats, Côte d’Ivoire, 2013 , 2015, Emerging infectious diseases.

[22]  Nick Golding,et al.  Mapping the zoonotic niche of Lassa fever in Africa , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[23]  Donald S. Grant,et al.  Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever , 2015 .

[24]  H. Feldmann,et al.  A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses , 2015, PLoS neglected tropical diseases.

[25]  L. Moses,et al.  Sequence Variability and Geographic Distribution of Lassa Virus, Sierra Leone , 2015, Emerging infectious diseases.

[26]  Giovanni Lo Iacono,et al.  Using Modelling to Disentangle the Relative Contributions of Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever , 2015, PLoS neglected tropical diseases.

[27]  C. Goldsmith.  Morphologic Differentiation of Viruses beyond the Family Level , 2014, Viruses.

[28]  Ignacio S. Caballero,et al.  Lassa and Marburg viruses elicit distinct host transcriptional responses early after infection , 2014, BMC Genomics.

[29]  K. Eze,et al.  Acute abdominal pain in patients with lassa fever: Radiological assessment and diagnostic challenges , 2014, Nigerian medical journal : journal of the Nigeria Medical Association.

[30]  Pardis C Sabeti,et al.  Lassa Fever in Post-Conflict Sierra Leone , 2014, PLoS neglected tropical diseases.

[31]  O. Crasta,et al.  Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells Exposed to Lassa Virus and to the Attenuated Mopeia/Lassa Reassortant 29 (ML29), a Vaccine Candidate , 2013, PLoS neglected tropical diseases.

[32]  M. Oldstone,et al.  Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus. , 2013, Virology.

[33]  N. Sardesai,et al.  Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation , 2013, Vaccines.

[34]  L. Flatz,et al.  Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials , 2013, PLoS pathogens.

[35]  Joshua C. Johnson,et al.  Transcriptional Profiling of the Circulating Immune Response to Lassa Virus in an Aerosol Model of Exposure , 2013, PLoS neglected tropical diseases.

[36]  I. Lukashevich.  The search for animal models for Lassa fever vaccine development , 2013, Expert review of vaccines.

[37]  I. Lukashevich,et al.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. , 2012, Journal of vaccines & vaccination.

[38]  I. Lukashevich.  Advanced Vaccine Candidates for Lassa Fever , 2012, Viruses.

[39]  S. Günther,et al.  Rapid and Specific Detection of Lassa Virus by Reverse Transcription-PCR Coupled with Oligonucleotide Array Hybridization , 2012, Journal of Clinical Microbiology.

[40]  I. Lukashevich,et al.  Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. , 2012, Vaccine.

[41]  Y. Kawaoka,et al.  Identification of Cell Surface Molecules Involved in Dystroglycan-Independent Lassa Virus Cell Entry , 2011, Journal of Virology.

[42]  Donald S. Grant,et al.  Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection , 2011, Virology Journal.

[43]  D. Smee,et al.  Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever , 2011, PLoS neglected tropical diseases.

[44]  Cristina Marino Buslje,et al.  Molecular Determinants of Arenavirus Z Protein Homo-Oligomerization and L Polymerase Binding , 2011, Journal of Virology.

[45]  Pardis C Sabeti,et al.  Lassa hemorrhagic fever in a late term pregnancy from northern sierra leone with a positive maternal outcome: case report , 2011, Virology Journal.

[46]  James E. Robinson,et al.  Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: Case Report , 2011, Virology Journal.

[47]  Mark A. Smith,et al.  Pathogenesis of lassa fever in cynomolgus macaques , 2011, Virology Journal.

[48]  R. D. Allen,et al.  Evaluation of Lassa antiviral compound ST-193 in a guinea pig model , 2011, Antiviral Research.

[49]  I. Lukashevich,et al.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. , 2011, Vaccine.

[50]  M. Buchmeier,et al.  Conserved Residues in Lassa Fever Virus Z Protein Modulate Viral Infectivity at the Level of the Ribonucleoprotein , 2011, Journal of Virology.

[51]  H. Feldmann,et al.  Rapid detection of Lassa virus by reverse transcription‐loop‐mediated isothermal amplification , 2011, Microbiology and immunology.

[52]  D. Bausch,et al.  Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  S. Günther,et al.  Domain Structure of Lassa Virus L Protein , 2010, Journal of Virology.

[54]  R. Charrel,et al.  The N-Terminal Domain of the Arenavirus L Protein Is an RNA Endonuclease Essential in mRNA Transcription , 2010, PLoS pathogens.

[55]  S. Günther,et al.  Laboratory Diagnosis of Lassa Fever, Liberia , 2010, Emerging infectious diseases.

[56]  S. Günther,et al.  Improved Detection of Lassa Virus by Reverse Transcription-PCR Targeting the 5′ Region of S RNA , 2010, Journal of Clinical Microbiology.

[57]  Rosamund F. Lewis,et al.  Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study , 2009, PLoS neglected tropical diseases.

[58]  Sara E. Miller,et al.  Modern Uses of Electron Microscopy for Detection of Viruses , 2009, Clinical Microbiology Reviews.

[59]  Baochuan Lin,et al.  Testing and Validation of High Density Resequencing Microarray for Broad Range Biothreat Agents Detection , 2009, PloS one.

[60]  W. Ian Lipkin,et al.  Genetic Detection and Characterization of Lujo Virus, a New Hemorrhagic Fever–Associated Arenavirus from Southern Africa , 2009, PLoS pathogens.

[61]  N. Tordo,et al.  Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys , 2009, Journal of Virology.

[62]  D. Smee,et al.  T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections , 2009, Antiviral Research.

[63]  D. Rogers,et al.  Risk Maps of Lassa Fever in West Africa , 2009, PLoS neglected tropical diseases.

[64]  P. Okokhere,et al.  Sensorineural hearing loss in Lassa fever: two case reports , 2009, Journal of medical case reports.

[65]  D. Smee,et al.  Treatment of Late Stage Disease in a Model of Arenaviral Hemorrhagic Fever: T-705 Efficacy and Reduced Toxicity Suggests an Alternative to Ribavirin , 2008, PloS one.

[66]  K. Mansfield,et al.  Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. , 2008, Vaccine.

[67]  M. Wilda,et al.  Mapping of the Tacaribe Arenavirus Z-Protein Binding Sites on the L Protein Identified both Amino Acids within the Putative Polymerase Domain and a Region at the N Terminus of L That Are Critically Involved in Binding , 2008, Journal of Virology.

[68]  S. M. Amberg,et al.  Identification of a Broad-Spectrum Arenavirus Entry Inhibitor , 2008, Journal of Virology.

[69]  R. Charrel,et al.  Phylogeny of the genus Arenavirus. , 2008, Current opinion in microbiology.

[70]  S. Günther,et al.  RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[71]  T. Ksiazek,et al.  High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. , 2007, The Journal of infectious diseases.

[72]  I. Lukashevich,et al.  A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. , 2007, Vaccine.

[73]  O. Ogbu,et al.  Lassa fever in West African sub-region: an overview. , 2007, Journal of vector borne diseases.

[74]  C. Drosten,et al.  Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[75]  D. Smee,et al.  Combinatorial Ribavirin and Interferon Alfacon-1 Therapy of Acute Arenaviral Disease in Hamsters , 2006, Antiviral chemistry & chemotherapy.

[76]  J. Weber,et al.  Identification of an N-Terminal Trimeric Coiled-Coil Core within Arenavirus Glycoprotein 2 Permits Assignment to Class I Viral Fusion Proteins , 2006, Journal of Virology.

[77]  M. Georges-Courbot,et al.  Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. , 2006, Microbes and infection.

[78]  V. Deubel,et al.  A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. , 2006, Virology.

[79]  I. Lukashevich,et al.  A Live Attenuated Vaccine for Lassa Fever Made by Reassortment of Lassa and Mopeia Viruses , 2005, Journal of Virology.

[80]  B. Mothé,et al.  Development of a New Vaccine for the Prevention of Lassa Fever , 2005, PLoS medicine.

[81]  F. Uckun,et al.  Zidampidine, an aryl phosphate derivative of AZT: in vivo pharmacokinetics, metabolism, toxicity, and anti-viral efficacy against hemorrhagic fever caused by Lassa virus. , 2005, Bioorganic & medicinal chemistry.

[82]  J. McCormick.  Clinical, epidemiologic, and therapeutic aspects of Lassa fever , 2005, Medical Microbiology and Immunology.

[83]  F. Hufert,et al.  Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies , 2005, Archives of Virology.

[84]  F. Uckun,et al.  Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus , 2004, BMC infectious diseases.

[85]  J. McCormick,et al.  Lassa fever vaccine , 2004, Expert review of vaccines.

[86]  A. Hoerauf,et al.  Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. , 2004, Virology.

[87]  M. Georges-Courbot,et al.  Lassa Virus Infection of Human Dendritic Cells and Macrophages Is Productive but Fails to Activate Cells1 , 2004, The Journal of Immunology.

[88]  Debbie Baglole,et al.  Lassa fever: epidemiology, clinical features, and social consequences , 2003, BMJ : British Medical Journal.

[89]  J. C. de la Torre,et al.  The small RING finger protein Z drives arenavirus budding: Implications for antiviral strategies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Christian Drosten,et al.  Rapid Detection and Quantification of RNA of Ebola and Marburg Viruses, Lassa Virus, Crimean-Congo Hemorrhagic Fever Virus, Rift Valley Fever Virus, Dengue Virus, and Yellow Fever Virus by Real-Time Reverse Transcription-PCR , 2002, Journal of Clinical Microbiology.

[91]  J. McCormick,et al.  Lassa fever. , 2002, Current topics in microbiology and immunology.

[92]  P. Jahrling,et al.  Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses , 2001, Journal of Virology.

[93]  N. Seidah,et al.  The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[95]  I. Lukashevich,et al.  Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. , 2001, Journal of human virology.

[96]  T. Ksiazek,et al.  Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. , 2001, Vector borne and zoonotic diseases.

[97]  L. Hutwagner,et al.  Effective Vaccine for Lassa Fever , 2000, Journal of Virology.

[98]  Stuart T. Nichol,et al.  Genetic Diversity among Lassa Virus Strains , 2000, Journal of Virology.

[99]  T. Ksiazek,et al.  Diagnosis and Clinical Virology of Lassa Fever as Evaluated by Enzyme-Linked Immunosorbent Assay, Indirect Fluorescent-Antibody Test, and Virus Isolation , 2000, Journal of Clinical Microbiology.

[100]  A. Hoerauf,et al.  Characterization of Human CD4+ T-Cell Clones Recognizing Conserved and Variable Epitopes of the Lassa Virus Nucleoprotein , 2000, Journal of Virology.

[101]  L. Xia,et al.  Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein. , 2000, Vaccine.

[102]  R Langer,et al.  Functional arteries grown in vitro. , 1999, Science.

[103]  J. Meulen,et al.  Detection of Lassa Virus Antinucleoprotein Immunoglobulin G (IgG) and IgM Antibodies by a Simple Recombinant Immunoblot Assay for Field Use , 1998, Journal of Clinical Microbiology.

[104]  J. Chang-Claude,et al.  Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. , 1996, The American journal of tropical medicine and hygiene.

[105]  D. Brown,et al.  Early diagnosis of Lassa fever by reverse transcription-PCR , 1994, Journal of clinical microbiology.

[106]  K. Hummel,et al.  Baculovirus expression of the glycoprotein gene of Lassa virus and characterization of the recombinant protein. , 1992, Virus research.

[107]  J. McCormick,et al.  Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys , 1992, Journal of medical virology.

[108]  F. Byl,et al.  Audiometric Comparison of Lassa Fever Hearing Loss and Idiopathic Sudden Hearing Loss: Evidence for Viral Cause , 1992, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[109]  J. McCormick,et al.  Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. , 1991, The Journal of general virology.

[110]  F. Hufert,et al.  Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction , 1990, Journal of clinical microbiology.

[111]  D. Kochhar.  Effects of exposure to high concentrations of ribavirin in developing embryos , 1990, The Pediatric infectious disease journal.

[112]  G. Barber,et al.  IDENTIFICATION OF LASSA FEVER VIRUS INFECTION WITH RECOMBINANT NUCLEOCAPSID PROTEIN ANTIGEN , 1989, The Lancet.

[113]  H. Morrison,et al.  Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. , 1989, Virology.

[114]  J. Frame.  Clinical features of Lassa fever in Liberia. , 1989, Reviews of infectious diseases.

[115]  L. Brammer,et al.  Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[116]  J. B. McCormick,et al.  A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. , 1988, BMJ.

[117]  G. Lloyd,et al.  VACCINIA RECOMBINANT EXPRESSING LASSA-VIRUS INTERNAL NUCLEOCAPSID PROTEIN PROTECTS GUINEAPIGS AGAINST LASSA FEVER , 1987, The Lancet.

[118]  J. McCormick,et al.  A case-control study of the clinical diagnosis and course of Lassa fever. , 1987, The Journal of infectious diseases.

[119]  J. McCormick,et al.  Clinical virology of Lassa fever in hospitalized patients. , 1987, The Journal of infectious diseases.

[120]  E. S. Smith,et al.  A prospective study of the epidemiology and ecology of Lassa fever. , 1987, The Journal of infectious diseases.

[121]  P. Jahrling,et al.  Experimental studies of arenaviral hemorrhagic fevers. , 1987, Current topics in microbiology and immunology.

[122]  J. McCormick,et al.  Lassa virus hepatitis: a study of fatal Lassa fever in humans. , 1986, The American journal of tropical medicine and hygiene.

[123]  J. McCormick,et al.  COMPARISON OF LASSA, MOBALA, AND IPPY VIRUS REACTIONS BY IMMUNOFLUORESCENCE TEST , 1985, The Lancet.

[124]  P. Jahrling,et al.  Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. , 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[125]  P. Jahrling,et al.  Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. , 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[126]  J. Maiztegui,et al.  IMPORTANCE OF DOSE OF NEUTRALISING ANTIBODIES IN TREATMENT OF ARGENTINE HAEMORRHAGIC FEVER WITH IMMUNE PLASMA , 1984, The Lancet.

[127]  P. Jahrling,et al.  Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain , 1984, Infection and immunity.

[128]  J. Gonzalez,et al.  Mobala virus: Biological and physicochemical properties of a new arenavirus isolated in the Central African Republic , 1984 .

[129]  J. Frame,et al.  The use of Lassa fever convalescent plasma in Nigeria. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[130]  J. McCormick,et al.  Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. , 1983, The American journal of tropical medicine and hygiene.

[131]  P. Jahrling.  Protection of lassa virus‐infected guinea pigs with lassa‐immune plasma of guinea pig, primate, and human origin , 1983, Journal of medical virology.

[132]  A. Anusz.  [Lassa fever]. , 1981, Pielegniarka i polozna.

[133]  G. van der Groen,et al.  A comparison of indirect immunofluorescence and electron microscopy for the diagnosis of some haemorrhagic viruses in cell cultures. , 1981, Journal of virological methods.

[134]  P. Jahrling,et al.  Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. , 1980, The Journal of infectious diseases.

[135]  J. Maiztegui,et al.  EFFICACY OF IMMUNE PLASMA IN TREATMENT OF ARGENTINE HÆMORRHAGIC FEVER AND ASSOCIATION BETWEEN TREATMENT AND A LATE NEUROLOGICAL SYNDROME , 1979, The Lancet.

[136]  F. Murphy,et al.  Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. , 1975, Bulletin of the World Health Organization.

[137]  H. Bourne,et al.  Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. , 1970, The American journal of tropical medicine and hygiene.